NCT00653952View on ClinicalTrials.gov

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

PHASE3TerminatedINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

May 31, 1997

Study Completion Date

April 30, 2000

Conditions

Ovarian Neoplasms

Interventions

DRUG

CAELYX

Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year

DRUG

Paclitaxel HCl

Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sequus Pharmaceuticals

INDUSTRY

collaborator

ALZA

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00653952 - CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | Biotech Hunter | Biotech Hunter